After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy under wraps, GlaxoSmithKline has pulled back part of the covers to reveal that drisapersen did in fact hit the primary endpoint on walking distance.
San Diego-based Ambrx welcomed an influx of cash for the further development of its drug-delivery technology: antibody drug conjugates, or ADCs.
The two groups have been working together for the past decade, helping build the city-state's reputation for R&D.
Device, diagnostics and drug companies should be working together and sharing intellectual property at a much sooner point in their research, argues Dr. Andrew von Eschenbach, who ran the FDA from 2005 to 2009.
Roche has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' antisense programs for Huntington's disease. In the deal, the latest in a lengthy string for the Carlsbad, CA-based biotech company, Isis gains $30 million upfront with the rest payable on promised milestones.
BSD Medical inked a wide-ranging deal with Japanese med tech giant Terumo to distribute one of its signature tumor ablation devices in Europe, Western Asia and North Africa.
Global CRO InVentiv Health is shipping out its sample management business to J. Knipper and focusing instead on its other clinical and commercial offerings.
President Barack Obama's highly anticipated BRAIN initiative--short for Brain Research Through Advancing Innovative Neurotechnologies--has the lofty goal of mapping the human brain in hopes of finding new treatments for diseases like Alzheimer's, Parkinson's and other neurological disorders.
Astellas Pharma has wagered on antibody drug conjugate tech from the San Diego biotech startup Ambrx, paying $15 million upfront and committing up to $285 million more in their collaboration focused in oncology. And it's more proof that major pharma outfits are keen on the advantages of pairing targeted antibodies with potent drug payloads to treat cancer.
Agios has teamed up with Foundation Medicine to find patients with the genetic profiles most suited to treatment on Agios therapies concerning two cancer metabolism targets.